Burden of Migraine in Europe Using Self-Reported Digital Diary Data from the Migraine Buddy© Application

Abstract

IntroductionMigraine is a neurological disease characterized by recurring attacks that can cause severe disabling pain. This study described the burden of migraine as reported by individuals with migraine in the real world using a mobile application.MethodsA retrospective, cross-sectional analysis was conducted using data captured through the Migraine Buddy© smartphone application from adult, self-diagnosed individuals with migraine in 17 European countries. Data were analyzed descriptively for the most recent 28-day period reported by users (n = 3900) during the study period (June 2015–July 2016) who were randomly selected on the basis of data completeness (completion rates > 70%) and stratified by migraine headache days/month: 4–7 episodic migraine (EM; n = 1500), 8–14 EM (n = 1500), and chronic migraine (≥ 15; CM; n = 900).ResultsMore than 95% of users reported that migraine negatively affected their daily activities during at least one migraine attack. Attacks affected 50.5% (184.4 days/year), 26.9% (98 days/year), and 14.5% (53 days/year) of the year among CM, 8–14 EM, and 4–7 EM groups, respectively. On average, 44.8% CM, 40.9% 8–14 EM, and 34.7% of 4–7 EM sufferers, respectively, reported anxiety and/or depression symptoms during migraine attacks. Social or home activities, productivity, and sleep were highly affected, regardless of migraine frequency. Employed respondents (n = 3106) reported an average of 2.3 workdays missed per month and that at least one in four migraines led to work absenteeism; these migraines were commonly reported to have at least moderate to severe levels of pain, corresponding to the inability of persons to perform some or even any activities. Triptans (68%), opioids (46%), and nonsteroidal anti-inflammatory drugs (45%) were self-reported as the most common medicines used.ConclusionsThis study, leveraging patient-reported data collected through a mobile application, demonstrates the high burden and impact of migraine on health-related quality of life, work productivity, and overall well-being of individuals suffering from migraines.FundingNovartis Pharma AG, Switzerland.

Migraine treatment and healthcare costs: retrospective analysis of the China Health Insurance Research Association (CHIRA) database

“…Surveys of migraine patients attending hospital neurology departments in mainland China have also found triptan use to be rare [21,22]. In contrast, triptans are among the most commonly prescribed acute medications for migraine in Europe, the US, and Japan [17,19,23,24]. The lower rate of triptan use in China may be explained by barriers to access owing to limited triptan availability in most hospitals and pharmacies.…”

Economic burden of migraine in Latvia and Lithuania: direct and indirect costs

“…Data was retrieved from the 2005 American Migraine Prevalence and Prevention (AMPP) study.2.815.202.91Steiner et al [35] c 8271 participants from 9 EU countries (Austria 644; France 876; Germany 318; Italy 487; Lithuania 573; Luxembourg 1833; Netherlands 2414; Spain 999; United Kingdom 127).12.8Ayzenberg et al [7] d 2725 adults from Russia (participants aged 18–65 years from 35 cities and nine rural areas; door-to-door survey). Of these, 1273 reported headaches.0.8Vo et al [27] e 218 patients with migraine; 2018 patients without migraine (France 39; Germany 59; UK 67; Italy 31; Spain 22).7.9925.7012.55Vo et al [37] f 3106 Migraine Buddy© Smartphone users with paid work from 17 European countries.19.852.827.6Martelletti et al [32] g 6534 patients with migraine from 31 countries worldwide being employed full-time or part time.28.8 a, b, c, d, e, f, g Details of deriving the annual number of days missed from work is reported in Additional file 1…”

<p>An Investigation into the Prevalence of Migraine and Its Prophylactic Treatment Patterns in the Czech Republic: An Observational Study</p>

“…There have been various studies across Europe and in other continents comparing the clinical and economic burden of migraine using various strategies as aforementioned. 12,14,15 The Burden of Episodic and Chronic Migraine in Europe (BECOME) study evaluated the burden of migraine across Notes: a Cumulative prophylactic line: 0, no prophylactic medication substances used; ≥1, first and subsequent prophylactic line; ≥2, second and subsequent prophylactic line; ≥3, third and subsequent prophylactic line; ≥4, fourth and subsequent prophylactic line. Abbreviations: n, number of migraine patients by cumulative prophylactic line; N, total number of migraine patients; %, percentage of migraine patients with cumulative prophylactic lines out of the overall number of migraine patients with respect to the analysis approach and by the analysis population; SD, standard deviation.…”